<n-docbody><doc bill="Y"><content.metadata.block><cmd.identifiers><cmd.cites><cmd.second.line.cite><bop/><bos/>Multidistrict Lit Man § 5:44<eos/><eop/></cmd.second.line.cite></cmd.cites></cmd.identifiers></content.metadata.block><prop.block><prop.head toc-guid=""><bop/><bos/><headtext>Multidistrict Litigation Manual</headtext><eos/><eop/></prop.head><content.metadata.block><cmd.dates><cmd.currency.default iso.d="20190501"><bop/><bos/>May 2019 Update<eos/><eop/></cmd.currency.default></cmd.dates></content.metadata.block><author.line><bop/><bos/><author>David F. Herr[<footnote.reference refid="If48bae516b3e11e99b03e53d6dd36aa2">a0</footnote.reference>]</author><eos/><eop/></author.line><prop.head toc-guid="I97b7f560933b11da99e2b07024dacc26"><bop/><bos/><label.name>Part</label.name><label.designator>I.</label.designator><headtext>Handling Cases Before the Judicial Panel on Multidistrict Litigation</headtext><eos/><eop/></prop.head><prop.head toc-guid="Id8e3eb20933b11da99e2b07024dacc26"><bop/><bos/><label.name>Chapter</label.name><label.designator>5.</label.designator><headtext>Factors in Deciding Whether Transfer Is Appropriate</headtext><eos/><eop/></prop.head></prop.block><message.block><include.copyright n-include_collection="w_wlnv_msg" n-include_guid="I1DA35ED81DD211B281BAD200220BDFCA">Copyright (c) 2017 Thomson/RIA All rights reserved.</include.copyright></message.block><section><section.front><doc.title toc-guid="I94f30033e1e311da9c26e67ca3b71335"><head parent="doc.title"><bop/><bos/><label.name>§ </label.name><label.designator>5:44.</label.designator><headtext>Arguments rejected by the Panel—Differences in the actions</headtext><eos/><eop/></head></doc.title></section.front><section.body><para><bop/><bos/><paratext>Other differences in the actions are similarly not considered fatal to transfer. <eos/><bos/>The Panel consistently looks to the requirement that at least some common factual issue exist before ordering transfer, but has equally consistently recognized that there is no “predominance” requirement for common issues.[<eos/><bos/><footnote.reference refid="If48bd5606b3e11e99b03e53d6dd36aa2">1</footnote.reference>] The Panel has pointed out that these differences can be handled by the case management orders entered in the transferee court. <eos/><bos/>For example, where actions present both common issues and individual issues, the transferee court can allow discovery on non-common issues to proceed concurrently with common-issue discovery.[<eos/><bos/><footnote.reference refid="If48bfc706b3e11e99b03e53d6dd36aa2">2</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>The inclination of the Panel to rely on the ability of the transferee judge to deal with differences in the actions has become more pronounced as the Panel has amassed experience with the proceedings in the transferee courts and the transferee judges have demonstrated great ability to manage complex dockets. <eos/><bos/>The Panel has repeatedly pointed out that transferee judges can order separate tracks for the cases,[<footnote.reference refid="If48c23806b3e11e99b03e53d6dd36aa2">3</footnote.reference>] and the Panel recognizes that transferee judges can recommend remand when common issue discovery and similar common issue litigation is completed.[<eos/><bos/><footnote.reference refid="If48c23816b3e11e99b03e53d6dd36aa2">4</footnote.reference>] The Panel observed:</paratext><display.quote><para><paratext><begin.quote ID="QT_0001"/>We note that the MDL-1598 transferee court can employ various pretrial techniques—such as establishing separate discovery and/ or motion tracks—to efficiently manage this litigation. <eos/><bos/>In any event, we leave the extent and manner of coordination or consolidation of these actions to the discretion of the transferee court.<eos/><bos/><end.quote refid="QT_0001"/>[<footnote.reference refid="If48c23826b3e11e99b03e53d6dd36aa2">5</footnote.reference>]</paratext></para></display.quote><paratext>The extent of coordination is a matter the Panel leaves to the transferee court, but it notes that it is aware of the broad array of tools available.[<eos/><bos/><footnote.reference refid="If48c23836b3e11e99b03e53d6dd36aa2">6</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>Similarly, the Panel has rejected the notion that the actions have to be identical.[<eos/><bos/><footnote.reference refid="If48c4a906b3e11e99b03e53d6dd36aa2">7</footnote.reference>] For example, the Panel has centralized actions despite the argument that the laws of different jurisdictions apply to the actions.[<eos/><bos/><footnote.reference refid="If48c4a916b3e11e99b03e53d6dd36aa2">8</footnote.reference>] In another docket, the Panel rejected the argument that the products involved were different, there were different defendants, and likely would be different measures of damages. <eos/><bos/>The Panel nonetheless ordered transfer.[<eos/><bos/><footnote.reference refid="If48c4a926b3e11e99b03e53d6dd36aa2">9</footnote.reference>] The presence of unique state-law issues in some of the actions does not prevent transfer.[<eos/><bos/><footnote.reference refid="If48c4a936b3e11e99b03e53d6dd36aa2">10</footnote.reference>] Where there are different facts, or a statute applies differently to some of the actions, transfer may still be ordered.[<eos/><bos/><footnote.reference refid="If48c4a946b3e11e99b03e53d6dd36aa2">11</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>Another option for the Panel is to recognize that differences exist, and treat the cases differently in the process of ordering transfer. <eos/><bos/>In one case involving multiple different drugs and defendants, the Panel grouped actions against one defendant relating to two drugs, and ordered transfer of those actions. <eos/><bos/>As to a group of other actions against other drugs that the Panel found did not share common issues, the Panel declined to transfer.[<eos/><bos/><footnote.reference refid="If48c71a06b3e11e99b03e53d6dd36aa2">12</footnote.reference>] In another docket comprising nine actions arising from a aircraft crash the Panel centralized the crash cases but excluded a contractual indemnity case.[<eos/><bos/><footnote.reference refid="If48c71a16b3e11e99b03e53d6dd36aa2">13</footnote.reference>] In one docket the Panel centralized 29 actions, but excluded one case that involved a completely different injury and therefore defect.[<eos/><bos/><footnote.reference refid="If48c71a26b3e11e99b03e53d6dd36aa2">14</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>Despite the Panel&apos;s unwillingness to consider minor differences in actions as a reason to deny centralization, where the actions are fundamentally different, it is still likely not to order transfer.[<eos/><bos/><footnote.reference refid="If48c71a36b3e11e99b03e53d6dd36aa2">15</footnote.reference>]</paratext><eos/><eop/></para></section.body></section><author.footnotes><footnote ID="If48bae516b3e11e99b03e53d6dd36aa2"><label.designator>a0</label.designator><footnote.body><para><bop/><bos/><paratext>Maslon Edelman Borman &amp; Brand, LLP, Minneapolis, Minnesota.<eos/></paratext><eop/></para></footnote.body></footnote></author.footnotes><footnote.block><footnote ID="If48bd5606b3e11e99b03e53d6dd36aa2"><label.designator>1</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914046" w-serial-number="2011788242" w-seq-number="00001" w-ref-type="RP" w-pub-number="0004637" ID="I813d66a16b3e11e99f73e2698c313519">In re Katz Interactive Call Processing Patent Litigation, 481 F. Supp. 2d 1353 (J.P.M.L. 2007)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2004638068" w-seq-number="00002" w-ref-type="RP" w-pub-number="0004637" ID="I813d66a36b3e11e99f73e2698c313519">In re Deep Vein Thrombosis Litigation, 323 F. Supp. 2d 1378 (J.P.M.L. 2004)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2001473152" w-seq-number="00003" w-ref-type="RP" w-pub-number="0004637" ID="I813d66a56b3e11e99f73e2698c313519">In re Phenylpropanolamine (PPA) Products Liability Litigation, 173 F. Supp. 2d 1377 (J.P.M.L. 2001)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48bfc706b3e11e99b03e53d6dd36aa2"><label.designator>2</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914046" w-serial-number="2033539095" w-seq-number="00004" w-ref-type="RP" w-pub-number="0007903" ID="I813f62716b3e11e99f73e2698c313519">In re AndroGel Products Liability Litigation, 24 F. Supp. 3d 1378 (J.P.M.L. 2014)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2033539088" w-seq-number="00005" w-ref-type="RP" w-pub-number="0007903" ID="I813f62736b3e11e99f73e2698c313519">In re Keurig Green Mountain Single-Serve Coffee Antitrust Litigation, 24 F. Supp. 3d 1361 (J.P.M.L. 2014)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2019111918" w-seq-number="00006" w-ref-type="RP" w-pub-number="0004637" ID="I813f62756b3e11e99f73e2698c313519">In re Bank of America Corp. Securities, Derivative and Employee Retirement Income Sec. Act (ERISA) Litigation, 626 F. Supp. 2d 1327 (J.P.M.L. 2009)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2019111935" w-seq-number="00007" w-ref-type="RP" w-pub-number="0004637" ID="I813f62776b3e11e99f73e2698c313519">In re Citigroup, Inc., Auction Rate Securities (ARS) Marketing Litigation (No. II), 626 F. Supp. 2d 1329 (J.P.M.L. 2009)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2016771267" w-seq-number="00008" w-ref-type="RP" w-pub-number="0004637" ID="I813f62796b3e11e99f73e2698c313519">In re Municipal Mortg. &amp; Equity, LLC, Securities and Derivative Litigation, 571 F. Supp. 2d 1373 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2015776116" w-seq-number="00009" w-ref-type="RP" w-pub-number="0004637" ID="I813f627b6b3e11e99f73e2698c313519">In re Pet Food Products Liability Litigation, 544 F. Supp. 2d 1378 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2015776114" w-seq-number="00010" w-ref-type="RP" w-pub-number="0004637" ID="I813f627d6b3e11e99f73e2698c313519">In re Genetically Modified Rice Litigation, 543 F. Supp. 2d 1375 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2015395207" w-seq-number="00011" w-ref-type="RP" w-pub-number="0004637" ID="I813f627f6b3e11e99f73e2698c313519">In re Gadolinium Contrast Dyes Products Liability Litigation, 536 F. Supp. 2d 1380 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2015730424" w-seq-number="00012" w-ref-type="RP" w-pub-number="0004637" ID="I813f62816b3e11e99f73e2698c313519">In re Oxycontin Antitrust Litigation, 542 F. Supp. 2d 1359 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2015776111" w-seq-number="00013" w-ref-type="RP" w-pub-number="0004637" ID="I813f62836b3e11e99f73e2698c313519">In re Ford Motor Co. Speed Control Deactivation Switch Products Liability Litigation, 543 F. Supp. 2d 1373 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2014605397" w-seq-number="00014" w-ref-type="RP" w-pub-number="0004637" ID="I813f62856b3e11e99f73e2698c313519">In re U.S. Foodservice, Inc., Pricing Litigation, 528 F. Supp. 2d 1370 (J.P.M.L. 2007)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2010617135" w-seq-number="00015" w-ref-type="RP" w-pub-number="0004637" ID="I813f62876b3e11e99f73e2698c313519">In re Department of Veterans Affairs (VA) Data Theft Litigation, 461 F. Supp. 2d 1367 (J.P.M.L. 2006)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2010225831" w-seq-number="00016" w-ref-type="RP" w-pub-number="0004637" ID="I813f62896b3e11e99f73e2698c313519">In re Pharmacy Ben. Managers, 452 F. Supp. 2d 1352 (J.P.M.L. 2006)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2008986103" w-seq-number="00017" w-ref-type="RP" w-pub-number="0004637" ID="I813f628b6b3e11e99f73e2698c313519">In re Bayou Hedge Funds Investment Litigation, 429 F. Supp. 2d 1374 (J.P.M.L. 2006)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2007921050" w-seq-number="00018" w-ref-type="RP" w-pub-number="0004637" ID="I813f628d6b3e11e99f73e2698c313519">In re Ameriquest Mortg. Co. Mortg. Lending Practices Litigation, 408 F. Supp. 2d 1354 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2007915636" w-seq-number="00019" w-ref-type="RP" w-pub-number="0004637" ID="I813f628f6b3e11e99f73e2698c313519">In re Delphi Corp. Securities, Derivative and “ERISA” Litigation, 403 F. Supp. 2d 1358 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2007603807" w-seq-number="00020" w-ref-type="RP" w-pub-number="0004637" ID="I813f62916b3e11e99f73e2698c313519">In re Ford Motor Co. Speed Control Deactivation Switch Products Liability Litigation, 398 F. Supp. 2d 1365 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2007602298" w-seq-number="00021" w-ref-type="RP" w-pub-number="0004637" ID="I813f62936b3e11e99f73e2698c313519">In re M3Power Razor System Marketing &amp; Sales Practices Litigation, 398 F. Supp. 2d 1363 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2007565831" w-seq-number="00022" w-ref-type="RP" w-pub-number="0004637" ID="I813f62956b3e11e99f73e2698c313519">In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation, 398 F. Supp. 2d 1356 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2006265212" w-seq-number="00023" w-ref-type="RP" w-pub-number="0004637" ID="I813f62976b3e11e99f73e2698c313519">In re Insurance Brokerage Antitrust Litigation, 360 F. Supp. 2d 1371 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2006209073" w-seq-number="00024" w-ref-type="RP" w-pub-number="0004637" ID="I813f62996b3e11e99f73e2698c313519">In re Polychloroprene Rubber (CR) Antitrust Litigation, 360 F. Supp. 2d 1348 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2004638068" w-seq-number="00025" w-ref-type="RP" w-pub-number="0004637" w-pinpoint-page="1380" ID="I813f629b6b3e11e99f73e2698c313519">In re Deep Vein Thrombosis Litigation, 323 F. Supp. 2d 1378, 1380 (J.P.M.L. 2004)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2001473152" w-seq-number="00026" w-ref-type="RP" w-pub-number="0004637" ID="I813f629d6b3e11e99f73e2698c313519">In re Phenylpropanolamine (PPA) Products Liability Litigation, 173 F. Supp. 2d 1377 (J.P.M.L. 2001)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2004168728" w-seq-number="00027" w-ref-type="RP" w-pub-number="0004637" ID="I813f629f6b3e11e99f73e2698c313519">In re Janus Mut. Funds Inv. Litigation, 310 F. Supp. 2d 1359 (J.P.M.L. 2004)</cite.query>); <cite.query w-src-number="0304914046" w-serial-number="1976102845" w-seq-number="00028" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1404" ID="I813f62a16b3e11e99f73e2698c313519">In re Smith Patent Litigation, 407 F. Supp. 1403, 1404 (J.P.M.L. 1976)</cite.query>. <eos/><bos/>For an example of how the transferee court can treat different groups of <case.history>transferred</case.history> cases differently, see <cite.query w-src-number="0304914046" w-serial-number="2007679916" w-seq-number="00029" w-ref-type="RP" w-pub-number="0000344" ID="I813f62a36b3e11e99f73e2698c313519">In re Urethane Antitrust Litigation, 232 F.R.D. 681 (D. Kan. 2005)</cite.query>. <eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c23806b3e11e99b03e53d6dd36aa2"><label.designator>3</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914046" w-serial-number="2037790700" w-seq-number="00030" w-ref-type="RP" w-pub-number="0007903" ID="I8141d3716b3e11e99f73e2698c313519">In re McCormick &amp; Company, Inc., Pepper Products Marketing and Sales Practices Litigation, 148 F. Supp. 3d 1364 (J.P.M.L. 2015)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2033539095" w-seq-number="00031" w-ref-type="RP" w-pub-number="0007903" ID="I8141d3736b3e11e99f73e2698c313519">In re Androgel Products Liability Litigation, 24 F. Supp. 3d 1378 (J.P.M.L. 2014)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2033539088" w-seq-number="00032" w-ref-type="RP" w-pub-number="0007903" ID="I8141d3756b3e11e99f73e2698c313519">In re Keurig Green Mountain Single-Serve Coffee Antitrust Litigation, 24 F. Supp. 3d 1361 (J.P.M.L. 2014)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2030316404" w-seq-number="00033" w-ref-type="RP" w-pub-number="0004637" ID="I8141d3776b3e11e99f73e2698c313519">In re Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, 936 F. Supp. 2d 1379 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2029837285" w-seq-number="00034" w-ref-type="RP" w-pub-number="0004637" ID="I8141d3796b3e11e99f73e2698c313519">In re Hyundai and Kia Fuel Economy Litigation, 923 F. Supp. 2d 1364 (J.P.M.L. 2013)</cite.query> (separate tracks might deal with one “advanced” action); <cite.query w-src-number="0304914046" w-serial-number="2012539199" w-seq-number="00035" w-ref-type="RP" w-pub-number="0004637" ID="I8141d37b6b3e11e99f73e2698c313519">In re Rembrandt Technologies, LP, Patent Litigation, 493 F. Supp. 2d 1367 (J.P.M.L. 2007)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2012573746" w-seq-number="00036" w-ref-type="RP" w-pub-number="0004637" ID="I8141d37d6b3e11e99f73e2698c313519">In re Kugel Mesh Hernia Patch Products Liability Litigation, 493 F. Supp. 2d 1371 (J.P.M.L. 2007)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2011788242" w-seq-number="00037" w-ref-type="RP" w-pub-number="0004637" ID="I8141d37f6b3e11e99f73e2698c313519">In re Katz Interactive Call Processing Patent Litigation, 481 F. Supp. 2d 1353 (J.P.M.L. 2007)</cite.query> (transferee court can order separate tracks for non-common issues); <cite.query w-src-number="0304914046" w-serial-number="2006294262" w-seq-number="00038" w-ref-type="RP" w-pub-number="0004637" ID="I8141d3816b3e11e99f73e2698c313519">In re Acacia Media Technologies Corp. Patent Litigation, 360 F. Supp. 2d 1377 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2004341818" w-seq-number="00039" w-ref-type="RP" w-pub-number="0004637" ID="I8141d3836b3e11e99f73e2698c313519">In re Ephedra Products Liability Litigation, 314 F. Supp. 2d 1373 (J.P.M.L. 2004)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2003568371" w-seq-number="00040" w-ref-type="RP" w-pub-number="0004637" ID="I8141d3856b3e11e99f73e2698c313519">In re Medical Waste Services Antitrust Litigation, 277 F. Supp. 2d 1382 (J.P.M.L. 2003)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c23816b3e11e99b03e53d6dd36aa2"><label.designator>4</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g</ital>., <cite.query w-src-number="0304914046" w-serial-number="2038226767" w-seq-number="00041" w-ref-type="RP" w-pub-number="0007903" ID="I81430bf16b3e11e99f73e2698c313519">In re Daily Fantasy Sports Marketing and Sales Practices Litigation, 158 F. Supp. 3d 1375 (J.P.M.L. 2016)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2036887277" w-seq-number="00042" w-ref-type="RP" w-pub-number="0007903" ID="I81430bf36b3e11e99f73e2698c313519">In re Fluoroquinolone Products Liability Litigation, 122 F. Supp. 3d 1378 (J.P.M.L. 2015)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2030316404" w-seq-number="00043" w-ref-type="RP" w-pub-number="0004637" ID="I81430bf56b3e11e99f73e2698c313519">In re Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, 936 F. Supp. 2d 1379 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2012539199" w-seq-number="00044" w-ref-type="RP" w-pub-number="0004637" ID="I81430bf76b3e11e99f73e2698c313519">In re Rembrandt Technologies, LP, Patent Litigation, 493 F. Supp. 2d 1367 (J.P.M.L. 2007)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2012573746" w-seq-number="00045" w-ref-type="RP" w-pub-number="0004637" ID="I81430bf96b3e11e99f73e2698c313519">In re Kugel Mesh Hernia Patch Products Liability Litigation, 493 F. Supp. 2d 1371 (J.P.M.L. 2007)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2011788242" w-seq-number="00046" w-ref-type="RP" w-pub-number="0004637" ID="I81430bfb6b3e11e99f73e2698c313519">In re Katz Interactive Call Processing Patent Litigation, 481 F. Supp. 2d 1353 (J.P.M.L. 2007)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c23826b3e11e99b03e53d6dd36aa2"><label.designator>5</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914046" w-serial-number="2004341818" w-seq-number="00047" w-ref-type="RP" w-pub-number="0004637" ID="I8143f6516b3e11e99f73e2698c313519">In re Ephedra Products Liability Litigation, 314 F. Supp. 2d 1373 (J.P.M.L. 2004)</cite.query>, citing <cite.query w-src-number="0304914046" w-serial-number="1974105890" w-seq-number="00048" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1384" ID="I8143f6536b3e11e99f73e2698c313519">In re Equity Funding Corp. of America Securities Litigation, 375 F. Supp. 1378, 1384-85 (J.P.M.L. 1973)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c23836b3e11e99b03e53d6dd36aa2"><label.designator>6</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914046" w-serial-number="2041399152" w-seq-number="00049" w-ref-type="RP" w-pub-number="0007903" ID="I8144b9a16b3e11e99f73e2698c313519">In re Stryker Orthopaedics LFIT V40 Femoral Head Products Liability Litigation, 249 F. Supp. 3d 1353 (U.S.J.P.M.L. 2017)</cite.query> (recognizing that transferee judge may establish separate tracks for different cases); <cite.query w-src-number="0304914046" w-serial-number="2039935883" w-seq-number="00050" w-ref-type="RP" w-pub-number="0007903" ID="I8144b9a36b3e11e99f73e2698c313519">In re Sunedison, Inc., Securities Litigation, 214 F. Supp. 3d 1350 (U.S.J.P.M.L. 2016)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2033539095" w-seq-number="00051" w-ref-type="RP" w-pub-number="0007903" ID="I8144b9a56b3e11e99f73e2698c313519">In re: AndroGel Products Liability Litigation, 24 F. Supp. 3d 1378 (U.S.J.P.M.L. 2014)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2010225831" w-seq-number="00052" w-ref-type="RP" w-pub-number="0004637" ID="I8144b9a76b3e11e99f73e2698c313519">In re Pharmacy Ben. Managers, 452 F. Supp. 2d 1352 (J.P.M.L. 2006)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2006243939" w-seq-number="00053" w-ref-type="RP" w-pub-number="0004637" ID="I8144b9a96b3e11e99f73e2698c313519">In re Vioxx Products Liability Litigation, 360 F. Supp. 2d 1352 (J.P.M.L. 2005)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c4a906b3e11e99b03e53d6dd36aa2"><label.designator>7</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914046" w-serial-number="2031812549" w-seq-number="00054" w-ref-type="RP" w-pub-number="0004637" ID="I8145cb116b3e11e99f73e2698c313519">In re North Sea Brent Crude Oil Futures Litigation, 978 F. Supp. 2d 1384 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2028469742" w-seq-number="00055" w-ref-type="RP" w-pub-number="0004637" ID="I8145cb136b3e11e99f73e2698c313519">In re Park West Galleries, Inc., Litigation, 887 F. Supp. 2d 1385 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2028341725" w-seq-number="00056" w-ref-type="RP" w-pub-number="0004637" ID="I8145cb156b3e11e99f73e2698c313519">In re Unified Messaging Solutions LLC Patent Litigation, 883 F. Supp. 2d 1340 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2027523154" w-seq-number="00057" w-ref-type="RP" w-pub-number="0004637" ID="I8145cb176b3e11e99f73e2698c313519">In re Bank of New York Mellon Corp. Foreign Exchange Transactions Litigation, 857 F. Supp. 2d 1371 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2016261914" w-seq-number="00058" w-ref-type="RP" w-pub-number="0004637" ID="I8145cb196b3e11e99f73e2698c313519">In re McDonald&apos;s French Fries Litigation, 560 F. Supp. 2d 1355 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2016261910" w-seq-number="00059" w-ref-type="RP" w-pub-number="0004637" ID="I8145cb1b6b3e11e99f73e2698c313519">In re “Agent Orange” Products Liability Litigation, 560 F. Supp. 2d 1352 (J.P.M.L. 2008)</cite.query> (differences in claims, method of exposure to chemical, and specific chemicals involved doesn&apos;t prevent transfer); <cite.query w-src-number="0304914046" w-serial-number="2004341694" w-seq-number="00060" w-ref-type="RP" w-pub-number="0004637" ID="I8145cb1d6b3e11e99f73e2698c313519">In re Zyprexa Products Liability Litigation, 314 F. Supp. 2d 1380 (J.P.M.L. 2004)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2001550460" w-seq-number="00061" w-ref-type="RP" w-pub-number="0004637" ID="I8145cb1f6b3e11e99f73e2698c313519">In re Inter-Op Hip Prosthesis Products Liability Litigation, 149 F. Supp. 2d 931 (J.P.M.L. 2001)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c4a916b3e11e99b03e53d6dd36aa2"><label.designator>8</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914046" w-serial-number="2007602298" w-seq-number="00062" w-ref-type="RP" w-pub-number="0004637" ID="I81468e616b3e11e99f73e2698c313519">In re M3Power Razor System Marketing &amp; Sales Practices Litigation, 398 F. Supp. 2d 1363 (J.P.M.L. 2005)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c4a926b3e11e99b03e53d6dd36aa2"><label.designator>9</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914046" w-serial-number="2009440538" w-seq-number="00063" w-ref-type="RP" w-pub-number="0004637" w-pinpoint-page="1354" ID="I814703916b3e11e99f73e2698c313519">In re Human Tissue Products Liability Litigation, 435 F. Supp. 2d 1352, 1354 (J.P.M.L. 2006)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c4a936b3e11e99b03e53d6dd36aa2"><label.designator>10</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914046" w-serial-number="2016274357" w-seq-number="00064" w-ref-type="RP" w-pub-number="0004637" ID="I814778c16b3e11e99f73e2698c313519">In re Merscorp Inc., et al., Real Estate Settlement Procedures Act (RESPA) Litigation, 560 F. Supp. 2d 1371 (J.P.M.L. 2008)</cite.query> (noting that transferee court can determine when remand is appropriate); <cite.query w-src-number="0304914046" w-serial-number="2015776117" w-seq-number="00065" w-ref-type="RP" w-pub-number="0004637" ID="I814778c36b3e11e99f73e2698c313519">In re Avandia Marketing, Sales Practices and Products Liability Litigation, 543 F. Supp. 2d 1376 (J.P.M.L. 2008)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c4a946b3e11e99b03e53d6dd36aa2"><label.designator>11</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914046" w-serial-number="2016771280" w-seq-number="00066" w-ref-type="RP" w-pub-number="0004637" ID="I814926716b3e11e99f73e2698c313519">In re Hawaiian and Guamanian Cabotage Antitrust Litigation, 571 F. Supp. 2d 1379 (J.P.M.L. 2008)</cite.query> (Jones Act applies differently to Hawaiian and Guamanian shipping routes, but common issues still warrant transfer).<eos/><bos/> Unspecified differences in the actions will similarly not prevent transfer. <eos/><bos/><ital>See, e.g</ital>., <cite.query w-src-number="0304914046" w-serial-number="2033539076" w-seq-number="00067" w-ref-type="RP" w-pub-number="0007903" ID="I814926736b3e11e99f73e2698c313519">In re National Collegiate Athletic Ass&apos;n Athletic Grant-in-Aid Cap Antitrust Litigation, 24 F. Supp. 3d 1366 (J.P.M.L. 2014)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c71a06b3e11e99b03e53d6dd36aa2"><label.designator>12</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914046" w-serial-number="2008986093" w-seq-number="00068" w-ref-type="RP" w-pub-number="0004637" ID="I814a10d16b3e11e99f73e2698c313519">In re Aredia and Zometa Products Liability Litigation, 429 F. Supp. 2d 1371 (J.P.M.L. 2006)</cite.query>. <eos/><bos/><ital>See also</ital> <cite.query w-src-number="0304914046" w-serial-number="2008553256" w-seq-number="00069" w-ref-type="RP" w-pub-number="0004637" ID="I814a10d36b3e11e99f73e2698c313519">In re Vioxx Marketing, Sales Practices and Products Liability Litigation, 416 F. Supp. 2d 1354 (J.P.M.L. 2006)</cite.query> (claims involving one drug transferred to join existing MDL docket; claims involving two other drugs separated and <case.history>remanded</case.history> to transferor courts).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c71a16b3e11e99b03e53d6dd36aa2"><label.designator>13</label.designator><footnote.body><para><bop/><bos/><paratext>See <cite.query w-src-number="0304914046" w-serial-number="2019170590" w-seq-number="00070" w-ref-type="RP" w-pub-number="0004637" ID="I814a86016b3e11e99f73e2698c313519">In re Helicopter Crash Near Weaverville, California, on August 5, 2008, 626 F. Supp. 2d 1355 (J.P.M.L. 2009)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c71a26b3e11e99b03e53d6dd36aa2"><label.designator>14</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914046" w-serial-number="2029361080" w-seq-number="00071" w-ref-type="RP" w-pub-number="0004637" ID="I814afb316b3e11e99f73e2698c313519">In re Nexium (Esomeprazole) Products Liability Litigation, 908 F. Supp. 2d 1362 (J.P.M.L. 2012)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If48c71a36b3e11e99b03e53d6dd36aa2"><label.designator>15</label.designator><footnote.body><para><bop/><bos/><paratext>See, e.g., <cite.query w-src-number="0304914046" w-serial-number="2034590187" w-seq-number="00072" w-ref-type="RP" w-pub-number="0007903" ID="I814bbe816b3e11e99f73e2698c313519">In re: National Ass&apos;n for Advancement of Multijurisdiction Practice Litigation, 52 F. Supp. 3d 1377 (U.S.J.P.M.L. 2014)</cite.query> (centralization denied where parties not the same and different rules were at issue in each jurisdiction); <cite.query w-src-number="0304914046" w-serial-number="2031270123" w-seq-number="00073" w-ref-type="RP" w-pub-number="0000999" ID="I814bbe836b3e11e99f73e2698c313519">In re Franck&apos;s Lab, Inc., Products Liability Litigation, 2013 WL 4048244 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2028341717" w-seq-number="00074" w-ref-type="RP" w-pub-number="0004637" ID="I814bbe856b3e11e99f73e2698c313519">In re George Clinton Judgment Enforcement Litigation, 883 F. Supp. 2d 1336 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2028341715" w-seq-number="00075" w-ref-type="RP" w-pub-number="0004637" ID="I814bbe876b3e11e99f73e2698c313519">In re Prescription Drug Co-Pay Subsidy Antitrust Litigation, 883 F. Supp. 2d 1334 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914046" w-serial-number="2028341704" w-seq-number="00076" w-ref-type="RP" w-pub-number="0004637" ID="I814bbe896b3e11e99f73e2698c313519">In re Honey Production Marketing and Sales Practices Litigation, 883 F. Supp. 2d 1333 (J.P.M.L. 2012)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote></footnote.block><content.metadata.block><cmd.royalty><cmd.copyright><bop/><bos/>Westlaw. © 2019 Thomson Reuters.  <eos/><bos/>No Claim to Orig. U.S. Govt. <eos/><bos/>Works.<eos/><eop/></cmd.copyright></cmd.royalty><cmd.identifiers><cmd.cites><cmd.first.line.cite><bop/><bos/>MDLITMAN § 5:44<eos/><eop/></cmd.first.line.cite></cmd.cites></cmd.identifiers></content.metadata.block></doc></n-docbody>
